Glenmark Pharma gets USFDA nod to market drug for relapsing multiple sclerosis
Published 10 Oct, 2020
By Staff Reporter
Drug major Glenmark Pharma on Wednesday said it has received final approval from the US health regulator for Dimethyl Fumarate delayed-release capsules, used for treatment of relapsing forms of multiple sclerosis in adults.